Advanced Extraction Protocol(s) for Analysis of Selected Antiviral Drug(s) (Entecavir).

Abstract

Entecavir (ENT) which have a structure that contain a guanosine nucleoside analog, is used as antiviral medication because of it is selectivity toward the chronic hepatitis B virus (HBV) that will inhibit it. A shift or earlier combination of lamivudine with ENT will result less resistance, comparable safety and more successful viral suppression compared to monotherapy, according to a clinical guideline. Additionally, there are several ways that ENT might degrade. Therefore, it is crucial to prepare certain materials to extracting the ENT. Molecular imprinting polymers (MIP) were created for this use through precipitation polymerization using the non-covalent method. Transmission electron microscopy (TEM) was used to characterise the polymer. The TEM results showed that polymer particles have a spherical shape and homogeneous size. Studies on ENT degradation by oxidation, basic and acidic force were performed. The stated drug, including its co-administered medication (lamivudine), and its breakdown products, were extracted from spiked plasma of human using the MIP. Using a recently developed HPLC technique that used a C18 column, gradient elution from the mobile phase made up of 0.1 percent phosphoric acid (H3PO4) in water : methanol with such flow rate of 1 ml/min, and UV absorbance around 254 nm, all eluents were examined. Forced degradation experiments were used to demonstrate the method's specificity as well as stability-indicating capacity. When MIP's selectivity was compared to that of ENT itself and degradation products, the difference was highly noticeable. Additionally, ENT was effectively extracted out from spiked plasma of human using MIP like an extractant, with such recovery rate of 88.32%